middle.news
AdAlta’s EW-001 Shows Durable Survival and Response in Mesothelioma Trial
9:18am on Monday 10th of August, 2026 AEST
•
Biotechnology
Read Story
AdAlta’s EW-001 Shows Durable Survival and Response in Mesothelioma Trial
9:18am on Monday 10th of August, 2026 AEST
Key Points
All five patients alive at July follow-up
30% of higher-dose patients survived 12+ months
50% overall response rate including 20% complete responses
Manufacturing transfer to Australia underway
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
AdAlta (ASX:1AD)
OPEN ARTICLE